Recently, Beijing-based Sinovac Biotech announced that the China Food and Drug Administration (FDA) has issued the Good Manufacturing Practices certificate for the company’s Enterovirus 71 vaccine. The vaccine is made from inactivated enterovirus 71.
Yang Guang, Sinovac investor relations director said that preclinical and clinical studies showed that the EV71 vaccine is effective and safe. This vaccine targets children that are aged 6 months to 3 years old.
The company intends to start the manufacture of the vaccine at the end of January this year.